INC Research Continues Expansion with Acquisition of Advanced Biologics

Acquisition of Advanced Biologics Gives INC Research Full-service Facility with Renowned Expertise

RALEIGH, NC – April 18, 2007 — INC Research®, a therapeutically focused contract research organization with a trusted process for delivering reliable results, today announced the strategic acquisition of Advanced Biologics to strengthen its Infectious Disease practice. Advanced Biologics is a full-service contract research organization (CRO) specializing in full-service clinical development to the pharmaceutical and biotechnology industries worldwide.

“Advanced Biologics has built a world-class team of therapeutic experts that are focused on the needs of its clients. We experience a tremendous amount of synergy with them on our approach to clinical trials – from how we kick-off a project, to how we develop a therapeutically-focused team, to how we ensure the accuracy and speed of the database lock, ” stated James T. Ogle, chief executive officer of INC Research. “By joining forces, our clients will greatly benefit from our expanded infectious disease capabilities.”

Advanced Biologics has full-service clinical development support for Phase I-IV clinical programs and has coordinated numerous IND, NDA, sNDA and ex-US submissions. Beyond its highly-respected infectious disease experience, the CRO has handled studies for drugs being developed for cancer, neurological diseases, urologic conditions, and women’s health. Advanced Biologics also has comprehensive biostatistics experience, which extends into the pharmaceutical industry and regulatory agencies. In addition, INC Research will fully leverage its Interactive Voice Response System (IVRS) technology, which provides patient randomization, stratification and data collection capabilities.

“We have already worked closely to ensure the integration of our teams, processes and technology is seamless for our clients. With our combined resources, we are well positioned to become an even stronger global force in the discovery and evaluation of new treatments for infectious diseases,” said Michael Corrado, president and CEO of Advanced Biologics and now the chief scientific officer of INC Research.

Advanced Biologics is the largest employer in New Hope, Pennsylvania. The Advanced Biologics name will be dropped when the acquisition is finalized, and the New Hope facility will continue to function as a full service drug development hub of operations, now serving as the seventh of INC Research’s North American locations.

INC Research’s investment banking and capital advisory team, Fairmount Partners, was instrumental in this acquisition process.


INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase 1 – Phase 4 programs in therapeutic areas of specialty, and in innovative pediatric trials. Our “Trusted Process™” methodology and therapeutic foresight leads our customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina, and now in 26 locations in 36 countries worldwide. For more information please visit

Principals of Fairmount Partners acted as advisors to INC Research in this transaction.

Fairmount Partners is a registered Broker Dealer, member FINRA ( and SIPC (

Contact: Neal McCarthy